 |
|
Adherence to Black Box Warnings for Prescription Medications in Outpatients
Karen E. Lasser, MD, MPH;
Diane L. Seger, RPh;
D. Tony Yu, MD, MPH;
Andrew S. Karson, MD, MPH;
Julie M. Fiskio, BS;
Andrew C. Seger, PharmD;
Nidhi R. Shah, MD, MPH;
Tejal K. Gandhi, MD, MPH;
Jeffrey M. Rothschild, MD, MPH;
David W. Bates, MD, MSc
Arch Intern Med. 2006;166:338-344.
Background Few data are available regarding the prevalence of potentially dangerous drug-drug, drug-laboratory, and drug-disease interactions among outpatients. Our objectives were to determine how frequently clinicians prescribe drugs in violation of black box warnings for these issues and to determine how frequently such prescribing results in harm.
Methods In an observational study of 51 outpatient practices using an electronic health record, we measured the frequency with which patients received prescriptions in violation of black box warnings for drug-drug, drug-laboratory, and/or drug-disease interactions. We performed medical record reviews in a sample of patients to detect adverse drug events. Multivariate analysis was conducted to assess the relationship of prescribing in violation of black box warnings to patient and clinician characteristics, adjusting for potential confounders and clustering.
Results Of 324 548 outpatients who received a medication in 2002, 2354 (0.7%) received a prescription in violation of a black box warning. After adjustment, receipt of medication in violation of a black box warning was more likely when patients were 75 years or older or female. The number of medications taken, the number of medical problems, and the site of care were also associated with violations. Less than 1% of patients who received a drug in violation of a black box warning had an adverse drug event as a result.
Conclusions About 7 in 1000 outpatients received a prescription violating a black box warning. Few incidents resulted in detectable harm.
Author Affiliations: Department of Medicine, Cambridge Health Alliance and Harvard Medical School, Cambridge, Mass (Dr Lasser); Partners HealthCare System, Wellesley, Mass (Mss Seger and Fiskio and Drs Seger and Bates); Division of General Medicine and Primary Care, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Drs Yu, Seger, Shah, Gandhi, Rothschild, and Bates); Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dr Karson); and Massachusetts College of Pharmacy and Health Sciences, Boston (Dr Seger).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Boxed warning inconsistencies between drug information resources and the prescribing information
Cheng et al.
Am J Health Syst Pharm 2011;68:1626-1631.
ABSTRACT
| FULL TEXT
Baseline and Follow-up Laboratory Monitoring of Cardiovascular Medications
Tjia et al.
The Annals of Pharmacotherapy 2011;45:1077-1084.
ABSTRACT
| FULL TEXT
Invited Commentary--Prescription Drug Label Adverse Events: A Call for Prioritization: Comment on "A Quantitative Analysis of Adverse Events and 'Overwarning' in Drug Labeling"
Cheng and Guglielmo
Arch Intern Med 2011;171:946-947.
FULL TEXT
Compliance with Platelet Count Monitoring Recommendations and Management of Possible Heparin-Induced Thrombocytopenia in Hospitalized Patients Receiving Low-Molecular-Weight Heparin
ten Berg et al.
The Annals of Pharmacotherapy 2009;43:1405-1412.
ABSTRACT
| FULL TEXT
A Randomized Trial of Electronic Clinical Reminders to Improve Medication Laboratory Monitoring
Matheny et al.
J Am Med Inform Assoc 2008;15:424-429.
ABSTRACT
| FULL TEXT
A Randomized Trial of the Effectiveness of On-demand versus Computer-triggered Drug Decision Support in Primary Care
Tamblyn et al.
J Am Med Inform Assoc 2008;15:430-438.
ABSTRACT
| FULL TEXT
The Utility of Adding Retrospective Medication Profiling to Computerized Provider Order Entry in an Ambulatory Care Population
Glassman et al.
J Am Med Inform Assoc 2007;14:424-431.
ABSTRACT
| FULL TEXT
Review of eight restricted-access programs and potential implications for pharmacy
Evans and Evans
Am J Health Syst Pharm 2007;64:1302-1310.
FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review
Kuperman et al.
J Am Med Inform Assoc 2007;14:29-40.
ABSTRACT
| FULL TEXT
Black Box Warnings and Prescribing Habits in an Outpatient Setting
Journal Watch Dermatology 2006;2006:3-3.
FULL TEXT
|
